As WT1 is ordinary over-expressing in AML and CML patients, targeting WT1 as possible tool against leukemic cells provides a new therapeutic option for AML and CML patients[19]. Here, WT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.